Table 2.
Rate of early adverse events and new or worsening neurological symptoms.
| Type of vaccine | Number of participants (%) | Number of participants who received one dose (%) | Number of participants who received two doses (%) | Number of participants (%) experiencing adverse events |
Number of participants (%) experiencing new or worsening neurological symptoms | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| One dose |
Two doses | Total | After first dose | After second dose | After both doses | Total | ||||
| Pfizer | 251 (57.3%) | 110 (43.8%) | 141 (56.2%) | 23 (9.2% |
52 (20.7%) | 75 (29.9%) | 15 (6%) |
18 (7.2%) | 5 (2%) |
48 (19.1%) |
| Moderna | 153 (34.9%) | 72 (47%) |
81 (53%) |
25 (16.4%) |
34 (22.2%) | 59 (38.6%) | 5 (3.3%) | 15 (9.8%) | 2 (1.3%) | 22 (14.4%) |
| AstraZeneca | 32 (7.3%) |
28 (87.5%) |
4 (12.5%) |
8 (25%) |
1 (3.1%) | 9 (28.1%) | 9 (28.1%) | 0 | 1 (3.1%) | 10 (31.3%) |
| Johnson & Johnson | 2 (0.4%) |
2 (100%) |
0 | 1 (50%) |
1 (50%) |
0 | 0 | |||